Joseph B. Conahan


Conahan, Joseph B.
Joseph Conahan's practice focuses on the representation of buyers, sellers and boards of directors in mergers, acquisitions, divestitures, joint ventures and other strategic transactions in the technology, life sciences, FinTech and financial services industries, as well as on counseling public companies on complex governance and disclosure matters.

Recent Highlights

Mr. Conahan recently has advised:

  • MKS Instruments, Inc. in its acquisition of Newport Corporation;
  • Cumberland Farms, Inc. in the sale of its Gulf Oil and Assured Deal business to affiliates of ArcLight Capital Partners;
  • The Medicines Company in the sale of its hemostasis business to subsidiaries of Mallinckrodt;
  • Analog Devices in its acquisition of the assets of Sand9;
  • Thermo Fisher Scientific in its acquisition of Advanced Scientifics;
  • Durata Therapeutics in its sale to Allergan (formerly Actavis);
  • Cynosure in the acquisition of the assets of Ellman International;
  • Kolltan Pharmaceuticals in its acquisition of Xetrios;
  • Analog Devices in its acquisition of Hittite Microwave;
  • Bottomline Technologies in its acquisition of Andera;
  • Thermo Fisher Scientific in the sale of its cell culture, gene modulation and magnetic beads businesses to GE Healthcare;
  • Analog Devices in the sale of its MEMS microphone business to InvenSense;
  • The Medicines Company in its acquisition of Recothrom from Bristol-Myers Squibb Company;
  • Dean Foods Company in the initial public offering and subsequent spin-off of its former subsidiary The WhiteWave Foods Company;
  • BAE Systems Safety Products in its sale to Takata Corporation;
  • Levitronix in the sale of its medical device business to Thoratec Corporation;
  • Constant Contact in its acquisition of the assets of Bantam Networks;
  • TARGUSinfo in its sale to Neustar;
  • Constant Contact in its acquisition of NutShell Mail;
  • Starent Networks in its sale to Cisco Systems; and
  • LTX in its business combination with Credence Systems.

Honors & Awards

  • Recipient of M&A Advisor's Sixth Annual 40 Under 40 Emerging Leaders Award

Community Involvement

Mr. Conahan's pro bono work includes the representation of organizations such as Bridge Boston Charter School, GlobalGiving Foundation and Boston Children's Chorus on a variety of matters.

Professional Activities

Mr. Conahan is a member of the Boston Bar Association and serves on the Mergers & Acquisitions Committee, and is co-chair of the Boston Bar Association's 2016 Mergers & Acquisitions Advisory Committee.

Publications & News


May 10, 2018

WilmerHale Counsels Braintree Laboratories in Acquisition by Sebela Pharmaceuticals

On May 1, 2018, Sebela Pharmaceuticals completed the acquisition of Braintree Laboratories Inc., a privately held specialty pharmaceutical company based in Braintree, Massachusetts. Braintree develops, manufactures and markets specialty pharmaceuticals in gastroenterology.

September 28, 2017

WilmerHale Represents CIRCOR in $855M Acquisition of Colfax’s Fluid Handling Business from Colfax Corp.

CIRCOR International, Inc.—a leading provider of flow control solutions and other highly engineered products for markets including oil & gas, aerospace, power, process and general industrial—announced that it has signed a definitive agreement to acquire Colfax Fluid Handling (CFH) from Colfax Corporation for approximately $855 million including cash, newly issued CIRCOR shares, and the assumption of pension plan liabilities linked to the CFH business.

April 28, 2017

2017 M&A Report

Our 2017 M&A Report provides a detailed global M&A market review and outlook. Other highlights include takeover defenses for public companies; key lessons for buyers and sellers considering earnouts; recent developments in merger control regulation; common interest privilege protection among deal parties; special considerations in California M&A deals; acquisition financial statement requirements for IPO companies; a comparison of deal terms in public and private acquisitions; and key terms and issues in sales of VC-backed companies.

July 26, 2016

WilmerHale Reps Analog Devices in $14.8B Acquisition of Linear Technology

Analog Devices Inc. announced that it would buy fellow chipmaker Linear Technology Corp. for about $14.8 billion, the latest deal in a wave of consolidation that has swept the semiconductor industry in the past two years.

May 3, 2016

WilmerHale Represents MKS Instruments in Acquiring Newport Corporation and Securing $980 Million Acquisition Financing

WilmerHale represented its long-time client MKS Instruments, Inc., a global technology provider, in closing its acquisition of Newport Corporation, a worldwide leader in photonics solutions, for approximately $905 million.

March 24, 2016

2016 M&A Report

Our 2016 M&A Report offers a detailed review of, and outlook for, the global M&A market. Other highlights include a comparison of deal terms in public and private acquisitions; updates on takeover defenses and public company deal litigation; practical guidance on avoiding antitrust violations in pre-merger integration planning; a look at what buyers need to know about appraisal claims in private company mergers; and a survey of key terms and issues in sales of VC-backed companies.

February 23, 2016

WilmerHale Advises MKS Instruments on $980 Million Acquisition of Newport Corporation

WilmerHale is advising its long-time client MKS Instruments, Inc. on its acquisition of Newport Corporation in an all-cash transaction valued at approximately $980 million.

January 13, 2016

Strong signs for New England M&A in 1H116

Partner David Westenberg offers insight into the 2016 capital markets outlook and Partner Joseph Conahan offers insight into the 2016 M&A outlook in this Deal Drivers piece written by Mergermarket, the leading provider of forward-looking M&A intelligence and data to M&A professionals and corporates.

December 21, 2015

The Medicines Company Agrees to Divest its Hemostasis Portfolio to Mallinckrodt plc

On December 18, The Medicines Company (NASDAQ:MDCO) announced that it entered into a purchase agreement pursuant to which certain subsidiaries of Mallinckrodt plc will acquire The Medicines Company’s global portfolio of three hemostasis products – RECOTHROM® Thrombin topical (Recombinant), PreveLeak™, and RAPLIXA™ (fibrin sealant) – for a total potential consideration of up to $410 million.

June 25, 2015

Joseph Conahan Honored Among M&A Advisor's 40 Under 40

Partner Joseph Conahan has been named to M&A Advisor's Sixth Annual 40 Under 40 Emerging Leaders Awards, a global recognition honoring leading dealmakers, legal advisors and others in the mergers and acquisitions, financing and turnaround markets.


Skip Navigation Links.


JD, magna cum laude, Georgetown University Law Center, 2004, Order of the Coif, Articles and Notes Editor, American Criminal Law Review

BS, cum laude, Georgetown University, 2001

Bar Admissions


District of Columbia


Skip Navigation Links.